Since January 2021, the
UCI has delegated the operational activities of its anti-doping program to the
International Testing Agency (ITA), while retaining results management and prosecution of anti-doping rule violations. Since then, clean cycling efforts have been led by the ITA Cycling Unit, dedicated specifically to all cycling disciplines. The UCI and ITA are bound by a services agreement that ensures the ITA acts independently.
Boldenone and its metabolites are listed on the Prohibited List under class S1.1 of anabolic androgenic steroids, according to the 2025 Prohibited List maintained by the World Anti-Doping Agency and adopted by the
UCI.
Before the positive test, Germán Darío Gómez had compiled a series of standout results in both stage races and one-day events, especially at under-23 level and later in the pro calendar. In 2021 he reached the podium in the road race at the Junior Pan-American Games under-23 and finished fifth in the time trial at the same event, adding seventh in the time trial at the 2023 Pan American Championships. In 2022 he confirmed his progression on the European calendar with two third places at the Trofeo Piva and the Trofeo Città di San Vendemiano.
In stage races, his performance improved season by season. In 2023 he finished fourth overall at the Giro Next Gen, one of the most significant results of his career. In 2024 he was sixth overall at the Tour du Rwanda, where he also took a fifth place on a stage. In 2025 he added several notable general classification results internationally, placing sixth at the Presidential Cycling Tour of Turkiye, 13th at the Tour de Langkawi and 12th at the Tour of Istanbul, along
with 10th at the Mercan’Tour Classic Alpes-Maritimes.